pralsetinib Clinical Research Trials | TrialX

Loading...

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (1)

Phase 3 (1)

Interventional (1)

Blueprint Medicines Corporation (1)

No (1)

No (1)

Adult (18+) (1)

I am/have/had

I am/have/hadadenocarcinoma

I am/have/hadmeasurable disease

I am/have/hadmetastasis

I am/have/hadnon-small cell lung cancer

I am/have/hadstage iv nsclc

I am/have/hadlung cancer

I am/have/hadneoplasms by site

I am/have/hadcancer treatment

I am/have/hadpulmonary disease

I am/have/hadmetastatic cancer

I am/have/hadcancer

I am/have/hadsmall cell lung cancer

I am/have/hadcarcinoma

I am/have/hadchemotherapy regimen

I am/have/hadcancer chemotherapy

I am/have/hadlung neoplasm

I am/have/hadhead and neck neoplasms

I am/have/hadlung disease

I am/have/hadcancer therapy

I am/have/hadstage iv non-small cell lung cancer

added new label for I am/have/had

more

I am looking for

I am looking forpemetrexed

I am looking forplatinum-based chemotherapy

I am looking forcarboplatin

I am looking forgemcitabine

I am looking foradjuvant

I am looking forret inhibitor

I am looking forimmunomodulators

I am looking forpembrolizumab

I am looking forpralsetinib

I am looking forimmunostimulants

I am looking formet inhibitor

I am looking forcisplatin

I am looking forimmunomodulator

added new label for I am looking for

more

Advanced Filters

Loading...

Found 1 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

AcceleRET Lung Study of Pralsetinib for 1L RET Fusion-positive Metastatic NSCLC

Patients who have centrally confirmed progressive disease on the control arm have the option to crossover to pralsetinib.

adenocarcinoma

measurable disease

ret inhibitor

neoplasms by site

lung cancer

0 views
19 Feb, 2024

Congrats! You have your own personal workspace now.

Learn more

© Copyright TrialX 2025 All rights reserved.